盐酸吉西他滨(Gemcitabine Hydrochloride) - 药物靶点：DNA x RNR_在研适应症：转移性乳腺癌，尿路上皮癌，胆道肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Gemcitabin、Gemcitabine I.V.、Gemcitabine hydrochloride (JAN/USP)

+ [16]

靶点

DNA x RNR

作用机制

DNA抑制剂(DNA抑制剂)、RNR抑制剂(核糖核苷酸还原酶复合体抑制剂)

治疗领域

肿瘤免疫系统疾病消化系统疾病+ [8]

在研适应症

转移性乳腺癌尿路上皮癌胆道肿瘤+ [58]

非在研适应症

异戊酸血症腺泡细胞癌晚期乳腺癌+ [113]

原研机构

Eli Lilly & Co.

在研机构

Bristol Myers Squibb Co.

National Cancer Institute

强生（中国）投资有限公司

+ [22]

非在研机构

Eisai, Inc.

Pfizer Inc.

GSK Plc

+ [47]

最高研发阶段批准上市

首次获批日期

美国 (1996-05-15),

转移性乳腺癌非小细胞肺癌胰腺腺癌

最高研发阶段(中国)临床3期

特殊审评突破性疗法 (美国)、孤儿药 (美国)、孤儿药 (日本)

登录后查看首次获批时间轴

结构

分子式C9H12ClF2N3O4

InChIKeyOKKDEIYWILRZIA-OSZBKLCCSA-N

CAS号122111-03-9

关联

1,726

项与盐酸吉西他滨相关的临床试验

NCT03541486 / Not yet recruiting临床2期IIT

XACT-Pancreas 2: Pharmacological Ascorbate, Gemcitabine, and Radiation Therapy for Pancreatic Cancer, Phase 2

Radiation therapy improves cancer cure rates by killing cancer cells but it also contributes to long-term side effects in cancer survivors by unintentionally damaging normal organs such as the intestine. This research will what side effects patients with cancer experience, if high dose vitamin C helps reduce these side effects, and if high dose vitamin C increases the survival of patients with pancreatic cancer. We will meet with patients during the study to better understand their experience during their cancer treatment. In the long term, our research could provide a new way help cancer survivors avoid many permanent side effects of cancer treatments.

开始日期2025-12-31

申办/合作机构

The Holden Comprehensive Cancer Center

NCT05700448 / Not yet recruiting临床3期

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

开始日期2024-07-01

申办/合作机构

基石药业（苏州）有限公司

NCT05314998 / Not yet recruiting临床3期IIT

An Open Labelled Phase III Adjuvant Trial of Disease-free Survival in Patients With Resected Pancreatic Ductal Adenocarcinoma Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

This is a multicentre open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria (control arm) or by a transcriptomic treatment specific stratification signature or TSS (test arm).

开始日期2024-06-15

申办/合作机构

Heidelberg University, U.S.

[+2]

100 项与盐酸吉西他滨相关的临床结果

登录后查看更多信息

100 项与盐酸吉西他滨相关的转化医学

登录后查看更多信息

100 项与盐酸吉西他滨相关的专利（医药）

登录后查看更多信息

432

项与盐酸吉西他滨相关的文献（医药）

2023-12-01·Journal of clinical medicine research

Treatment With Antitumor Agents Recommended by Cancer Genome Panel for Uterine Leiomyosarcoma

作者: Hayashi, Takuma ; Abiko, Kaoru ; Kishimoto, Naoya ; Konishi, Ikuo

To date, cancer genomic medicine, using cancer gene panel covered by health insurance from June 2019, has been performed for advanced malignant tumors under public medical insurance. In gynecology, the first-line treatment for uterine leiomyosarcomas, which is a mesenchymal uterine tumor, is surgery. In uterine leiomyosarcoma cases, recurrence is observed within 2 years postoperatively; however, to date, clinical trials have not shown efficacy with existing antitumor agents. We noted efficacy in two cases with advanced/recurrent uterine leiomyosarcoma using an antitumor agent selected on the basis of cancer gene panel testing results. Following uterine leiomyosarcoma diagnosis, they underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy as standard surgical treatment. After the surgical treatment, the imaging test revealed recurrent tumors; subsequently, they were treated with doxorubicin alone or doxorubicin combined with Gemzar. However, cancer genome gene panel test was performed because the malignant tumor worsened. Based on the cancer genome gene panel test results, the two cases with advanced uterine leiomyosarcoma were associated with increased tumor mutational burden (TMB) or pathogenic variants (PVs) of AKT serine/threonine kinase 1 (AKT1). Therefore, treatment with pembrolizumab, which is a drug covered by insurance for patients with TMB-high, or treatment with kinase inhibitors for patients with PVs in AKT, was considered. Cancer genomic medicine using cancer gene panel provides a new treatment strategy for intractable malignant tumors. This study aimed to discuss the usefulness of cancer genomic medicine by cancer gene panel testing using the cases of advanced and recurrence uterine leiomyosarcoma and the latest findings.

2023-08-01·Aktuelle Urologie

[First-line maintenance therapy of adult patients with BCG-naïve high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) - SunRISe-3 - AB 85/23 of AUO].

Article

2023-08-01·Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Radiolabeled gemcitabine hydrochloride as an imaging agent for lung cancer: Radiolabeling, quality control and cell incorporation studies

Article

作者: Ekinci, Meliha ; Santos-Oliveira, Ralph ; İlem-Özdemir, Derya

The development of new drugs that can specifically screen tumors is a global need. When it comes to lung cancer, which is the second main cause of cancer-related deaths, early detection of lung tumors using appropriate imaging is very important. In this study, gemcitabine hydrochloride (GCH) was radiolabeled with [^99mTc]Tc under different conditions (changing reducing agent, antioxidant agent, incubation time, pH, [^99mTc]Tc activity) and radiolabeling activity (quality control) using Radio Thin Layer Chromatography and paper electrophoresis. The results showed that the most stable complex ([^99mTc]Tc-GCH) was prepared using 0.015 mg of stannous chloride as a reducing agent, 0.01 mg of ascorbic acid as an antioxidant and 37 MBq activity at pH 7.4 after 15 min of incubation time. The complex remained stable for 6 h. Cell incorporation studies showed a six-fold higher uptake of [^99mTc]Tc-GCH in cancer (A-549) cells (38.42 ± 1.53) than healthy (L-929) cells (6.11 ± 0.17) have shown that it can. In addition, the different behaviors of R/H-[^99mTc]Tc confirmed the specificity of this newly developed radiopharmaceutical. Although these studies are preliminary, it has been concluded that [^99mTc]Tc-GCH may be a candidate drug for use in nuclear medicine, particularly in the diagnosis of lung cancer.

479

项与盐酸吉西他滨相关的新闻（医药）

2024-06-25

·PMLiVE

New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

The University of Glasgow and the NHS Greater Glasgow and Clyde have launched a mid-stage study to evaluate a new drug combination as a first-line treatment for patients living with metastatic pancreatic cancer. As part of the Precision-Panc Platform, the phase 2 PRIMUS-006 study will evaluate Eli Lilly and Genentech’s Gemzar (gemcitabine) in combination with Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Immodulon Therapeutics’ investigational IMM-101 in metastatic pancreatic ductal adenocarcinoma (PDAC). Currently the tenth most common cancer in the UK, pancreatic cancer is responsible for more than 10,000 new cases every year. Often fatal, PDAC is commonly found too late and does not respond well to treatments. Co-ordinated by the Glasgow Oncology Clinical Trials Unit, the new combination therapy will be evaluated in up to 50 patients diagnosed with metastatic PDAC who may not be able to receive current combination chemotherapy from up to 20 hospital sites in the UK. The chemotherapy drug Gemzar is indicated as a first-line treatment for a variety of cancers, including bladder, breast, pancreas, ovary and non-small-cell lung cancer, while Merck’s T-cell checkpoint inhibitor is used in cancer immunotherapy for multiple cancers, including melanoma, lung cancer, cervical cancer and certain types of breast cancer. Immodulon’s investigational IMM-101 is an immunomodulatory drug containing heat-killed, whole-cell Mycobacterium obuense, which is currently being evaluated in chemotherapy. Professor David Chang, chief investigator and professor, surgical oncology, Wolfson Wohl Cancer Research Centre, University of Glasgow and Glasgow Royal Infirmary, commented: “The… PRIMUS-006 study is an important milestone in the pursuit to develop new treatment options to improve the overall outcomes in patients diagnosed with pancreatic cancer.” Most recently, Merck’s Keytruda received approval from the US Food and Drug Administration in combination with carboplatin and paclitaxel, and then as a single agent, to treat adults with primary, advanced or recurrent endometrial carcinoma. Along with the PRIMUS-006 study, the therapy is also currently being studied in more than 1,600 clinical trials, including the phase 2b KEYNOTE-942 study evaluating Keytruda in combination with Merck and Moderna’s investigational skin cancer vaccine, mRNA-4157.

临床2期免疫疗法疫苗

2024-05-28

·FierceBiotech

Clinical-stage cancer biotech Actuate latest to eye summer IPO

Actuate Therapeutics hopes to use some of its IPO funds to initiate a phase 2 study assessing elraglusib in refractory Ewing sarcoma. Could the IPO window really be reopening for the summer? The second biotech proposition in May seems to suggest the public markets are regaining their allure. This time, it's Actuate Therapeutics, which has a glycogen synthase kinase‐3 beta (GSK-3β) drug called elraglusib in a phase 2 trial for pancreatic cancer. The Texas- and Ireland-based biotech hasn’t yet set out how many shares will be offered nor at what price but said in a related Securities and Exchange Commission filing (PDF) that the proceeds from an IPO would allow it to complete the midstage trial as well as a phase 1 dose- escalation trial in pediatric refractory cancer. The biotech also hopes to use some of the IPO funds to initiate a phase 2 portion of that study assessing elraglusib in refractory Ewing sarcoma. Elraglusib is designed to bind to GSK-3β, disrupting cancer pathways associated with the invasion of tumor cells and resistance to chemotherapeutic agents and radiation. In preclinical tests, the intravenous small molecule showed promise against diseases including urothelial cancer and renal cell carcinoma, leading Actuate to move it into human studies in 2018. The phase 2 pancreatic cancer study has already seen some success, demonstrating a 57% disease control rate and 39% objective response rate when given in combination with the chemotherapy Gemzar. A New Year resurgence of biotech IPOs died down by March. After a break, Actuate is the second company to have announced interest this month in going public. Third Rock Ventures and Johnson & Johnson-backed Rapport Therapeutics unveiled IPO ambitions to push its clinical-stage seizure disorder asset into phase 2 last week. While neither Rapport or Actuate have set out their IPO pricing, it doesn’t seem like either company has been put off by the mixed fortunes of this year’s first wave of publicly listed biotechs. While most of the January and February crop received warm reactions from the markets initially, their valuations have dropped off since. A Fierce Biotech analysis of data from S&P Capital IQ shows that only one company—CG Oncology—is still trading above its IPO price. It’s an even more impressive feat for CG considering the bladder-cancer-focused company was not only the first biotech to go public this year but also brought in the most money via a significantly upsized $380 million offering. Still, this month’s announcements by both Rapport and Actuate give credence to the predictions of Medicxi Partner Francesco De Rubertis, who told Fierce Biotech earlier this month that he expected the biotech IPO window to reopen this summer.

临床1期IPO临床2期

2024-05-27

·信狐药迅

两个优先1类：复星MEK1/2抑制剂复迈替尼两适应症、加科思KRAS 抑制剂格来雷塞提交上市申请|新受理（5.20-5.26）

本周药品注册受理数据，分门别类呈现，一目了然。(5.20-5.26）小编收到有些用户反应，不想收到咱们每周文章的推送提醒，而有些用户又特别需要这个提醒，在小编强烈要求下，我们给力的程序员终于实现了可以关闭提醒的功能，这个绝对全网独一家喔，不想收到提醒的，只要在信狐药迅对话框内回复关键词“拒收文章提醒”，那么就可以不受推送的打扰啦!新药上市申请药品名称企业注册分类受理号复迈替尼片上海复星医药产业发展有限公司1CXHS2400047复迈替尼片上海复星医药产业发展有限公司1CXHS2400046枸橼酸格来雷塞片北京加科思新药研发有限公司1CXHS2400044水合氯醛口服液成都亚中生物制药有限责任公司2.2CXHS2400045替妥尤单抗注射液信达生物制药(苏州)有限公司2.1CXSS2400050新药临床申请药品名称企业注册分类受理号YZG-331片中国医学科学院药物研究所1CXHL2400519ENN0403胶囊轶诺(浙江)药业有限公司1CXHL2400524DG01片苏州德亘生物医药有限公司1CXHL2400523DG01片苏州德亘生物医药有限公司1CXHL2400522BG-68501片百济神州(苏州)生物科技有限公司1CXHL2400521BG-68501片百济神州(苏州)生物科技有限公司1CXHL2400520HLX208片上海复宏汉霖生物技术股份有限公司1CXHL2400518注射用WE011上海宝龙药业股份有限公司1CXHL2400517SAL0120片深圳信立泰药业股份有限公司1CXHL2400513SAL0120片深圳信立泰药业股份有限公司1CXHL2400512XJN010鼻喷雾剂广州新济药业科技有限公司2.2CXHL2400526HKG-319国药瑞福莱药业有限公司2.2CXHL2400515HKG-319国药瑞福莱药业有限公司2.2CXHL2400514SMF-215江西施美药业股份有限公司2.3CXHL2400516青蒿琥酯片桂林南药股份有限公司2.4CXHL2400527米诺地尔泡沫剂(女用)山西振东安欣生物制药有限公司3CYHL2400101米诺地尔泡沫剂(男用)山西振东安欣生物制药有限公司3CYHL2400100甘露醇山梨醇注射液内蒙古白医制药股份有限公司3CYHL2400099HR19024注射液上海恒瑞医药有限公司2.2;2.4CXHL2400525重组破伤风疫苗(大肠埃希菌)远大赛威信生命科学(南京)有限公司1.2CXSL2400340LY01620南京吉迈生物技术有限公司1CXSL2400349注射用ZGGS18苏州泽璟生物制药股份有限公司1CXSL2400348注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2400347RC148注射液荣昌生物制药(烟台)股份有限公司1CXSL2400346注射用RC118荣昌生物制药(烟台)股份有限公司1CXSL2400345JH013注射液百泰生物药业有限公司1CXSL2400342SHR-3821注射液苏州盛迪亚生物医药有限公司1CXSL2400341注射用HS-20124常州恒邦药业有限公司1CXSL2400344GenSci098注射液长春金赛药业有限责任公司1CXSL2400343SHR-7787注射液上海恒瑞医药有限公司1CXSL2400336Obexelimab注射液上海泽纳仕生物科技有限公司1CXSL2400339DCTY1102注射液北京鼎成肽源生物技术有限公司1CXSL2400338SHR-7787注射液上海恒瑞医药有限公司1CXSL2400337IBI354信达生物制药(苏州)有限公司1CXSL2400335SHR-1819注射液广东恒瑞医药有限公司1CXSL2400334mp105深圳瀛晟生物医药有限公司1CXSL2400332SYS6020注射液石药集团中奇制药技术(石家庄)有限公司1CXSL2400333仿制药申请药品名称企业注册分类受理号盐酸甲氧氯普胺注射液北京民康百草医药科技有限公司3CYHS2401573乙酰半胱氨酸注射液湖北津药药业股份有限公司3CYHS2401572盐酸倍他司汀片上海理想制药有限公司3CYHS2401560吸入用盐酸丙卡特罗溶液成都天之翼尚品医药科技有限公司3CYHS2401557复方氨基酸(15AA-II)/葡萄糖(10%)电解质注射液山东齐都药业有限公司3CYHS2401556盐酸布比卡因注射液广州艾格生物科技有限公司3CYHS2401555复方氨基酸(15AA-II)/葡萄糖(10%)电解质注射液山东齐都药业有限公司3CYHS2401554盐酸布比卡因注射液广州艾格生物科技有限公司3CYHS2401553盐酸布比卡因注射液北京民康百草医药科技有限公司3CYHS2401571盐酸布比卡因注射液北京民康百草医药科技有限公司3CYHS2401570尼麦角林片海南通用三洋药业有限公司3CYHS2401569尼麦角林片海南通用三洋药业有限公司3CYHS2401567盐酸溴己新注射液黑龙江澳利达奈德制药有限公司3CYHS2401551氨溴特罗口服溶液山东新华制药股份有限公司3CYHS2401549吲哚布芬片河北龙海药业有限公司3CYHS2401547二硫化硒洗剂安徽省先锋制药有限公司3CYHS2401529二羟丙茶碱注射液广州合和医药有限公司3CYHS2401528洛索洛芬钠细粒剂浙江百代医药科技有限公司3CYHS2401527盐酸丙美卡因滴眼液浙江莎普爱思药业股份有限公司3CYHS2401525平衡盐冲洗液西安京西双鹤药业有限公司3CYHS2401523平衡盐冲洗液西安京西双鹤药业有限公司3CYHS2401522盐酸纳美芬注射液山东如至生物医药科技有限公司3CYHS2401539法莫替丁注射液北京格林意锐医药科技有限责任公司3CYHS2401538法莫替丁注射液北京格林意锐医药科技有限责任公司3CYHS2401537氨溴特罗口服溶液广东南国药业有限公司3CYHS2401536西咪替丁注射液南京斯泰尔医药科技有限公司3CYHS2401535盐酸异丙肾上腺素注射液湖南华纳大药厂股份有限公司3CYHS2401534盐酸异丙肾上腺素注射液湖南华纳大药厂股份有限公司3CYHS2401533倍他米松磷酸钠注射液成都瑞尔医药科技有限公司3CYHS2401520左乙拉西坦缓释片佛山德芮可制药有限公司3CYHS2401519左乙拉西坦缓释片佛山德芮可制药有限公司3CYHS2401517腺苷钴胺胶囊海南全星制药有限公司3CYHS2401521吗啉硝唑氯化钠注射液辽宁民康制药有限公司4CYHS2401574甲巯咪唑片江苏德源药业股份有限公司4CYHS2401563注射用盐酸吉西他滨江苏诚康药业有限公司4CYHS2401562复方甘草酸苷片北京远方通达医药技术有限公司4CYHS2401561枸橼酸莫沙必利片上海理想制药有限公司4CYHS2401559阿莫西林克拉维酸钾片浙江巨泰药业有限公司4CYHS2401558达格列净二甲双胍缓释片(I)河南立诺制药有限公司4CYHS2401568达格列净二甲双胍缓释片(IV)河南立诺制药有限公司4CYHS2401566注射用头孢唑肟钠武汉恒泰医药科技有限公司4CYHS2401565注射用头孢唑肟钠武汉恒泰医药科技有限公司4CYHS2401564左炔诺孕酮片武汉九珑人福药业有限责任公司4CYHS2401548拉莫三嗪分散片仁合益康集团有限公司4CYHS2401546头孢托仑匹酯颗粒北京诚济制药股份有限公司4CYHS2401545巴瑞替尼片江苏万邦生化医药集团有限责任公司4CYHS2401544巴瑞替尼片江苏万邦生化医药集团有限责任公司4CYHS2401543左氧氟沙星滴眼液海南斯达制药有限公司4CYHS2401542瑞舒伐他汀依折麦布片(Ⅱ)浙江诺得药业有限公司4CYHS2401541瑞舒伐他汀依折麦布片(I)浙江诺得药业有限公司4CYHS2401540氧山东宏运达赭山气体有限公司4CYHS2401552硫酸氨基葡萄糖胶囊浙江亚克药业有限公司4CYHS2401550盐酸羟考酮缓释片江苏恩华药业股份有限公司4CYHS2401532盐酸尼卡地平注射液浙江赛默制药有限公司4CYHS2401531艾考糊精腹膜透析液芜湖道润药业有限责任公司4CYHS2401530阿司匹林肠溶片江苏济茗医药有限公司4CYHS2401526替米沙坦氨氯地平片天津恒翊药业有限公司4CYHS2401524普拉洛芬滴眼液浙江视方极医药科技有限公司4CYHS2401518帕拉米韦氯化钠注射液仁合益康集团有限公司4CYHS2401516帕拉米韦氯化钠注射液仁合益康集团有限公司4CYHS2401515硫酸镁钠钾口服用浓溶液江苏广承药业有限公司4CYHS2401514非布司他片湖北亨迪药业股份有限公司4CYHS2401513非布司他片湖北亨迪药业股份有限公司4CYHS2401512硫酸氨基葡萄糖胶囊北京百美特生物制药有限公司4CYHS2401511达可替尼片山东朗诺制药有限公司4CYHS2401510达可替尼片山东朗诺制药有限公司4CYHS2401509复方托吡卡胺滴眼液苏州欧康维视生物科技有限公司4CYHS2401508进口申请药品名称企业注册分类受理号环磷酰胺片Baxter Oncology GmbH5.1JXHS2400036艾沙妥昔单抗注射液Sanofi Winthrop Industrie2.2JXSS2400044艾沙妥昔单抗注射液Sanofi Winthrop Industrie2.2JXSS2400043VSA001注射液Arrowhead Pharmaceuticals, Inc.1JXHL2400116Astegolimab注射液F. Hoffmann-La Roche Ltd1JXSL2400103Englumafusp alfa注射液F.Hoffmann-La Roche Ltd.1JXSL2400098ABBV-382注射液AbbVie Inc.1JXSL2400097Epcoritamab注射用浓溶液AbbVie Inc.2.2JXSL2400102Epcoritamab注射用浓溶液AbbVie Inc.2.2JXSL2400101Epcoritamab注射液AbbVie Inc.2.2JXSL2400100Epcoritamab注射液AbbVie Inc.2.2JXSL2400099中药相关申请药品名称企业注册分类受理号CRA杏林中医药科技(广州)有限公司1.2CXZL2400031CRA片杏林中医药科技(广州)有限公司1.2CXZL2400030不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市疫苗临床申请优先审批

100 项与盐酸吉西他滨相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01155	盐酸吉西他滨	L01BC05	DB00441

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
尿路上皮癌	日本	Eli Lilly & Co.	2008-11-25
胆道肿瘤	日本	Eli Lilly & Co.	2001-08-31
乳腺癌	日本	Eli Lilly & Co.	2001-08-31
淋巴瘤	日本	Eli Lilly & Co.	2001-08-31
卵巢癌	日本	Eli Lilly & Co.	2001-08-31
胰腺癌	日本	Eli Lilly & Co.	2001-08-31
转移性乳腺癌	美国	Eli Lilly & Co.	1996-05-15
非小细胞肺癌	美国	Eli Lilly & Co.	1996-05-15
胰腺腺癌	美国	Eli Lilly & Co.	1996-05-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性膀胱癌	临床3期	美国	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	中国	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	日本	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	阿根廷	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	比利时	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	巴西	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	德国	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	意大利	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	波兰	Janssen Research & Development LLC	2024-04-09
复发性膀胱癌	临床3期	罗马尼亚	Janssen Research & Development LLC	2024-04-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03451331 (CTgov)	临床2期	转移性尿路上皮癌	49	nivolumab+Carboplatin+Gemcitabine (Arm A)	製鏇構夢網窪廠醖製醖(鑰鏇獵醖鬱顧選餘鏇鑰) = 鹽構蓋鹽鑰鹹鏇願艱夢窪願蓋願餘網繭築獵獵 (襯淵鏇糧醖觸鏇糧簾積, 簾糧選蓋憲齋鹹觸壓構 ~ 築遞鬱鏇糧衊齋選鏇築) 更多	-	2024-05-16
				nivolumab+Gemcitabine+Oxaliplatin (Arm B)	製鏇構夢網窪廠醖製醖(鑰鏇獵醖鬱顧選餘鏇鑰) = 衊簾窪糧醖鏇餘窪範構窪願蓋願餘網繭築獵獵 (襯淵鏇糧醖觸鏇糧簾積, 鏇繭獵憲鬱顧製廠襯餘 ~ 艱構鹹廠鹹積網糧齋積) 更多
NCT01326871 (CTgov)	临床1/2期	输尿管肿瘤 \| 膀胱尿路上皮癌 \| 肾盂癌 ... 更多	68	Gemcitabine+cisplatin+ALT-801 (ALT-801 0.04 mg/kg With Cisplatin and Gemcitabine)	獵築廠鏇夢膚觸淵蓋淵(鑰選築簾糧廠顧築鬱餘) = 獵構觸繭鏇醖繭襯構廠願鏇醖膚艱蓋衊鑰壓築 (顧築選獵夢簾襯鬱顧廠, 廠簾遞範鏇餘顧製簾鑰 ~ 製構糧鹽築構鹽衊夢獵) 更多	-	2024-05-14
				Gemcitabine+cisplatin+ALT-801 (ALT-801 0.06 mg/kg With Cisplatin and Gemcitabine)	獵築廠鏇夢膚觸淵蓋淵(鑰選築簾糧廠顧築鬱餘) = 餘膚壓醖遞構淵鏇壓夢願鏇醖膚艱蓋衊鑰壓築 (顧築選獵夢簾襯鬱顧廠, 糧鑰淵鑰襯築製範範網 ~ 艱齋構夢築網艱製構繭) 更多
NCT04640623 (SunRISe-1, Biospace) 人工标引	临床2期	非肌层浸润性膀胱肿瘤	85	TAR-200	鏇鹽築艱夢繭鑰壓顧積(夢鑰艱簾築觸鑰鏇積廠) = 鏇衊膚淵膚醖顧艱構廠窪網顧壓糧選廠淵鬱顧 (夢觸廠製繭廠鹽窪築選 ) 更多	积极	2024-05-06
NCT04640623 (SunRISe-1, NEWS) 人工标引	临床2期	膀胱癌	58	TAR-200	餘淵顧遞觸築膚構觸衊(顧糧鏇觸衊衊壓壓鏇觸) = 蓋淵鹽廠憲製憲遞遞製願顧鬱餘顧鏇廠膚鬱蓋 (獵齋範醖襯範鏇顧糧鏇 )	积极	2024-05-02
NCT04088188 (CTgov)	临床1期	不可切除的肝内胆管癌 \| 晚期胆道癌 \| 转移性胆管癌	8	Ivosidenib+Gemcitabine+cisplatin (Arm A (Ivosidenib, Cisplatin, Gemcitabine))	醖構範憲願築遞齋憲蓋(蓋齋構鏇鹽蓋襯窪壓艱) = 觸範壓願遞憲製築憲壓鹽廠糧艱廠艱簾鏇鑰簾 (積鬱窪構廠顧鏇鑰鬱鹹, 憲繭顧築膚繭鏇蓋窪製 ~ 糧鬱遞鏇鹹蓋選積鹹築) 更多	-	2024-05-02
				Gemcitabine+cisplatin+Pemigatinib (Arm B (Pemigatinib, Cisplatin, Gemcitabine))	簾夢蓋襯遞積繭鏇鏇鏇(築鹽範鬱衊齋選夢齋鹽) = 壓襯積壓衊鑰壓壓廠願製獵製鑰醖構壓鏇積簾 (艱選憲鏇蓋襯鑰齋艱廠, 鹹鬱夢糧齋鹹獵鬱鹽鏇 ~ 蓋糧糧顧餘簾廠觸艱鬱) 更多
NCT03848182 (CTgov)	临床2期	胰腺癌	10	TT vaccine booster+gemcitabine	選醖鑰襯選夢積餘淵壓(艱願淵鬱夢襯網鹽獵廠) = 願艱鑰築簾鬱鏇鏇獵夢蓋遞餘鏇網遞鬱構醖窪 (淵簾積壓範餘願製築製, 夢鹹觸餘廠獵蓋憲艱壓 ~ 鑰鏇鹹衊鏇衊鏇艱獵憲) 更多	-	2024-04-18
NCT04430036 (CTgov)	临床2期	肌层浸润性膀胱癌	4	AGEN2034+gemcitabine+Cisplatin+AGEN1884	醖鑰範艱艱積顧簾製齋(繭製膚夢夢壓鏇窪衊壓) = 簾窪壓網築鬱獵遞憲壓艱糧觸鹹範繭膚簾簾膚 (簾憲繭簾膚鹽夢夢糧膚, 夢艱鹹鹽鬱衊鹹齋願醖 ~ 壓遞糧窪獵夢淵窪範遞) 更多	-	2024-04-04
NCT04313608 (CTgov)	临床1期	高级别B细胞淋巴瘤 \| 复发性弥漫性大B细胞淋巴瘤	23	Tocilizumab+Obinutuzumab+Gemcitabine+Glofitamab+Oxaliplatin (Arm A: Glofit-GemOx)	齋觸獵選淵餘蓋繭鑰鬱(網壓觸蓋築觸構艱積襯) = 夢繭壓齋齋夢鹽簾繭鏇願網衊醖襯廠廠蓋壓鹽 (積網鹽觸觸齋襯窪鹹餘, 網衊夢築蓋醖廠廠獵鹹 ~ 淵糧鹽蓋鏇範鑰觸蓋繭) 更多	-	2024-03-25
				Mosunetuzumab+Tocilizumab+Gemcitabine+Oxaliplatin (Arm B: Mosun-GemOx)	齋觸獵選淵餘蓋繭鑰鬱(網壓觸蓋築觸構艱積襯) = 壓簾選壓構範簾製鑰積願網衊醖襯廠廠蓋壓鹽 (積網鹽觸觸齋襯窪鹹餘, 襯網積顧鏇築壓齋鹹夢 ~ 齋繭艱鏇鹹鹽蓋廠鏇夢) 更多
NCT01897454 (CTgov)	临床2期	胰腺腺癌	23	Intensity-Modulated Radiation Therapy+Leucovorin Calcium+Gemcitabine Hydrochloride+oxaliplatin+Irinotecan Hydrochloride+fluorouracil	鹽願醖齋齋鬱窪構鏇鹹(鏇積夢窪願網繭艱廠衊) = 範艱獵齋鹹壓廠積窪廠餘夢醖糧鑰艱築鬱醖醖 (築醖築網壓範艱衊餘艱, 壓鬱觸構糧窪製觸鏇積 ~ 觸壓觸觸鑰艱積願築夢) 更多	-	2023-12-05
NCT03531320 (CTgov)	临床1/2期	晚期胆管癌 \| 胃肠道肿瘤	19	D07001-softgel capsules (Part 1:Dose-Escalation Phase)	糧淵鹽範觸鑰觸蓋醖鬱(選製壓窪膚顧製觸膚範) = 蓋簾簾餘窪廠選構廠齋簾簾窪餘鬱顧遞憲選襯 (獵範鹽範鑰鬱構廠網範, 鹽鏇衊簾淵襯積窪選願 ~ 齋憲範憲範醖壓窪鏇衊)	-	2023-11-24
				D07001-softgel capsules (Part 2: Dose-Expansion Phase (Phase 2))	選襯憲製鬱鹽積蓋簾夢(蓋觸鬱遞窪觸夢齋觸簾) = 觸艱選網網淵顧構糧襯獵繭襯憲鏇憲構鑰鹽廠 (簾廠築廠鑰鹽製蓋鹹糧, 壓範齋選衊膚壓構積憲 ~ 餘網網夢壓齋窪鏇廠網) 更多